Cell Bio Human Tech Co Ltd

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.36, below the median for the Textiles & Leather Goods industry. It holds 15.9 billion KRW in cash and equivalents, but after subtracting long-term debt of 20.5 billion KRW, net cash is negative, signaling potential liquidity constraints [doc:HA-latest]. The current ratio of 2.29 suggests adequate short-term liquidity to cover obligations, though the negative net cash position remains a concern [doc:HA-latest]. Profitability metrics show strong performance, with a return on equity of 15.37% and return on assets of 9.86%, both exceeding the industry median for ROE and ROA in the Textiles & Leather Goods sector. Operating income of 9.85 billion KRW and net income of 8.72 billion KRW reflect solid margins, though gross profit of 18.85 billion KRW suggests room for improvement in cost control [doc:HA-latest]. The company operates in a single business segment focused on mask pack materials and hydrocolloids, with no disclosed geographic revenue breakdown. This lack of diversification increases exposure to regional demand fluctuations and supply chain disruptions [doc:HA-latest]. Revenue of 51.07 billion KRW in the latest period indicates a stable growth trajectory, though no forward-looking guidance is provided. The company’s capital expenditure of -6.81 billion KRW suggests asset disposals or reduced investment in production capacity, which may impact long-term growth [doc:HA-latest]. Risk assessment highlights medium liquidity risk due to the negative net cash position and a current ratio that, while acceptable, does not fully offset the debt burden. Dilution risk is low, with no significant share issuance activity or dilution potential disclosed in the latest filings [doc:HA-latest]. No recent events, such as earnings calls, regulatory filings, or strategic announcements, are disclosed in the input data to provide insight into near-term operational or strategic developments [doc:HA-latest].